Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCR in MCL, CLL, and relapsed B-cell NHL
NCT00764517Phase 2Completed
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Aug 2008
- Primary completion
- Jan 2015
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat in mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), B-cell non-Hodgkin lymphoma, sponsored by OHSU Knight Cancer Institute. Started Aug 2008; status: completed.
02
Drugs
vorinostat
03
Conditions
mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT00764517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00764517.